165 - Long-Term Prognostic Analysis of Chemoradiotherapy vs. Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results from a Prospective Randomized Control Study
173 - Interplay of Radiation and Cyclophosphamide Doses on Local Control in Children with Group III Rhabdomyosarcoma: An Analysis of Studies from the Childrens Oncology Group
180 - Assessing the Tumor Visibility and Respiratory Motion of Liver Cancer Patients on Multi-Task MR and 4D-CT Imaging for Radiation Treatment Planning
Location: Room 152
Presenter: Oi Wai Chau, PhD – Mayo Clinic Alix School of Medicine
10:45 AM – 10:55 AM ET
214 - Transgender and Non-Binary Use of Gender-Affirming Hormone Therapy and Effects on PSA and Prostate Cancer Detection
Location: Room 140
Presenter: Paul Riviere, MD – UCSD Radiation Medicine and Applied Sciences
10:55 AM – 11:05 AM ET
215 - Centering Black Voices: Factors Influencing a Cancer Patients Decision to Join a Clinical Trial
Location: Room 140
Presenter: Charlyn Gomez, BS – University of Maryland School of Medicine
11:05 AM – 11:15 AM ET
216 - Identification of a High-Risk Population in the United States for Anti-EBV Serologic Screening for Nasopharyngeal Carcinoma
218a - Can Radiotherapy Quality Assurance (RT QA) Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries (LMICs) - Technical Results of the Second Phase of a Prospective International Ato
181 - Long-Term Patient-Reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial of Salvage Radiotherapy and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate Plus
182 - Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer
183 - Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher - Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials
184 - A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High Risk Prostate Cancer: Efficacy Results at Median 6 Y
186 - Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses
Location: Room 202
Presenter: Colin Belliveau, MD – Centre Hospitalier de l'Universite de Montreal (CHUM)
11:45 AM – 11:55 AM ET
187 - Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial
203 - Defining the Role of Radiotherapy for Indolent, Primary Cutaneous B-Cell Lymphoma - First Results from a Multicenter Registry by the International Lymphoma Radiation Oncology Group (ILROG)
189 - Hypofractionated Radiotherapy plus Concurrent Chemotherapy with or without Consolidation Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer (GASTO-1052)
Location: Room 207
Presenter: Hui Liu, MD, PhD – Sun Yat-Sen University Cancer Center
11:05 AM – 11:15 AM ET
190 - The Selective Personalized RadioImmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes
Location: Room 207
Presenter: Nitin Ohri, MD, MS – Montefiore Einstein Comprehensive Cancer Center
11:15 AM – 11:25 AM ET
191 - Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: FLARE-RT Mature Outcomes and Patterns of Failure
193 - Durvalumab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer: A Prospective, Single-Arm, Phase II Clinical Trial
Location: Room 207
Presenter: Wen Bin Shen, MD – The Fourth Hospital of Hebei Medical University
11:45 AM – 11:55 AM ET
194 - Simultaneous Integrated Boost vs. Conventional Radiotherapy for Patients with Limited-Stage Small Cell Lung Cancer: A Randomized, Non-Inferiority, Open-Label, Phase 3 Trial
Location: Room 207
Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC
10:45 AM – 10:55 AM ET
208 - Assessment of Circulating Tumor Cells in Oligometastatic Castration-Sensitive Prostate Cancer Patients from the ORIOLE Trial
211 - Prognostic Implications of Cerebrospinal Fluid Circulating Tumor DNA (CSF ctDNA) Following Radiation Therapy in Patients with Leptomeningeal Metastasis: Analysis of a Randomized Phase II Trial
Discussant: Kent Mouw, MD, PhD – Dana-Farber/Brigham and Women's Cancer Center
10:45 AM – 10:55 AM ET
195 - A Deep Learning-Driven Framework for Large Language Model-Assisted Automatic Target Volume Localization and Delineation for Enhancing Spinal Metastases Stereotactic Body Radiotherapy Workflow
196 - Identifying Candidates for Postoperative Radiotherapy in Patients with Non-Small Lung Cancer: Multicenter Deep Learning Model Development and Prospective Validation
LBA01 - Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer
224 - Natural History after Likely Cure vs. Recurrence vs. after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials
236 - "If You're Talking, I Think You're Muted:" Follow-Up Analysis of Weekly Peer Review Discussion and Deviation Detection after Transitioning from Virtual to In-Person Format
Location: Room 209
Presenter: Ryan Hughes, MD – Wake Forest University School of Medicine
3:00 PM – 3:10 PM ET
225 - Early Clinical Insights into FDG-Guided Radiotherapy Planning and Delivery on a Novel PET-Linac Platform in Patients with Lung and Bone Lesions: Pioneering Real-Time Biology-Guided Radiotherapy
Location: Room 145
Presenter: Bin Cai, PhD – University of Texas Southwestern Medical Center
3:10 PM – 3:20 PM ET
226 - Toward Adaptive Dose Painting with Hypoxia Biomarkers: Feasibility of Oxygen-Enhanced (OE)-MRI T1 Mapping on Low-Field MR-Linac
227 - Pathologic Response Prediction Value of 18f-Fapi PET/CT in ESCC Treated with Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial
238 - Single-Institution Phase 1/2 Prospective Trial Evaluating Three-Fraction Partial Breast Irradiation: Four Year Outcomes Including Quantitative Cosmesis and Patient-Reported Outcomes
Location: Room 202
Presenter: Silpa Raju, MD – Washington University in St. Louis
5:20 PM – 5:30 PM ET
239 - Clinical Outcomes of Patients with Early-Stage Breast Cancer Treated with Five-Fraction Partial Breast Irradiation vs. Intraoperative Radiation Therapy
240 - Long-Term Results of a Phase II Prospective Clinical Trial of Single-Fraction, High-Gradient Adjuvant Partial Breast Irradiation in Early-Stage, Hormone Sensitive Breast Cancer
Location: Room 202
Presenter: David Lakomy, MD – Washington University in St. Louis
5:40 PM – 5:50 PM ET
241 - Comparison of Acute and Late Toxicities with Daily vs. Every Other Day Five Fraction Partial Breast Radiation Therapy
255 - Initial Results of the Multicenter Phase II Trial of a Novel Hypofractionated Low-Dose Radiotherapy for Indolent Non-Hodgkin Lymphoma
Location: Room 144
Presenter: Xinyue Wang, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
5:40 PM – 5:50 PM ET
256 - A Proof-of-Principle Study of Split-Course Bridging Radiotherapy (SC-BRT) prior to Commercial CAR T-Cell Therapies for Relapsed or Refractory B-Cell Lymphomas: Results from Phase 1a Pilot Cohort
242 - Long-Term Outcomes of Postoperative Radiotherapy for Patients with pIIIA-N2 Non-Small Cell Lung Cancer after Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
243 - Long-Term Outcomes of a Prospective Randomized Trial of Passive Scattering Proton Therapy vs. Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
244 - The Impact of Prophylactic Bisphosphonates on Radiation-Induced Rib Fractures and Chest Wall Pain in Peripheral Lung Tumor SBRT: A Randomized, Double-Blind, Placebo-Controlled Study
246 - Exploratory Analysis of ctDNA and Imaging Response in the Phase I/II CHORUS Study of Canakinumab with Chemoradiation and Durvalumab Consolidation for Stage III NSCLC
247 - A Phase II Trial of 5-Day Neoadjuvant Radiation Therapy for Patients with High-Risk Primary Soft Tissue Sarcoma: Long-Term Follow-Up and Outcomes
248 - The Impact of Hypofractionated Pre-Operative Radiation Therapy on PD-L1 Expression in Soft Tissue Sarcomas
Location: Room 143
Presenter: Manpreet Bedi, MD, MS – Medical College of Wisconsin Affiliated Hospitals
5:20 PM – 5:30 PM ET
249 - Habitat Escalated Adaptive Therapy (HEAT): A Phase 2 Trial Utilizing Radiomic Habitat-Directed and Genomic-Adjusted Radiation Dose (GARD) Optimization for High-Grade Soft Tissue Sarcoma
Location: Room 143
Presenter: Arash Naghavi, MD, MS – H. Lee Moffitt Cancer Center and Research Institute
5:30 PM – 5:40 PM ET
250 - Reduction of Bone Fracture after Radiotherapy in Lower Extremity Soft Tissue Sarcoma after Implementing Bone Avoidance Objectives for Radiotherapy Planning
251 - Immune Profiling of "Radvax" Abscopal Responses in Metastatic Melanoma Patients Progressing on Anti-PD1 Therapy Treated with Hypofractionated Radiotherapy (HFRT) to One Lesion Combined with Pembrolizu
Location: Room 143
Presenter: John Lukens, MD – Hospital of the University of Pennsylvania
1018 - Dose-Escalated Hypofractionated Adaptive Radiotherapy (DEHART) and 60 Gy in 15 Fractions for Advanced Head and Neck Cancers: An Interim Analysis of a Phase I Trial
1021 - Prognostic Value of Image-Identified Extranodal Extension and Potential Role in Cn Classification in HPV-Negative Oropharyngeal Cancer: A Multi-Center Cohort Study
1023 - Treatment Response-Adapted Risk Index Model for Survival Prediction and Adjuvant Chemotherapy Selection in Nonmetastatic Nasopharyngeal Carcinoma
Location: Room 152
Presenter: Yang Liu, MD – Cancer Hospital Chinese Academy of Medical Sciences
5:35 PM – 5:55 PM ET
Questions and Answers
Location: Room 152
5:55 PM – 6:00 PM ET
Closing
Location: Room 152
5:00 PM – 5:05 PM ET
Introduction
Location: Room 147
5:05 PM – 5:10 PM ET
1024 - CT-Guided Online Adaptive Stereotactic Body Radiation Therapy for Liver Tumors